Olivier Glehen
奥利维耶·格雷安
MD, PhD
Professor of Surgery; Head, Department of Digestive Surgery外科学教授；消化外科主任
👥Biography 个人简介
Olivier Glehen is Professor of Surgery at Centre Hospitalier Lyon-Sud and one of Europe's foremost peritoneal oncology experts. He was principal investigator of the PRODIGE 7 phase III RCT, published in JAMA Surgery in 2021, which challenged the incremental value of oxaliplatin-based HIPEC when added to optimal CRS, prompting reassessment of HIPEC protocols worldwide and refining patient selection criteria.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PRODIGE 7 Trial – Challenging Oxaliplatin HIPEC
Led the PRODIGE 7 phase III RCT, which found that adding oxaliplatin-based HIPEC to CRS did not significantly improve overall survival compared to CRS alone in colorectal peritoneal metastases, prompting international debate on optimal HIPEC drug selection and surgical completeness.
French Multicenter Peritoneal Registry
Established and led the French multicenter registry for peritoneal surface malignancies, generating large-scale real-world outcome data used to refine national guidelines and patient selection criteria for CRS + HIPEC across multiple tumor types.
Peritoneal Mesothelioma CRS + HIPEC
Contributed major outcome analyses for malignant peritoneal mesothelioma treated with CRS + HIPEC, demonstrating improved survival with complete cytoreduction and informing European treatment guidelines.
Representative Works 代表性著作
Addition of hyperthermic intraperitoneal chemotherapy to cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer: a multi-institutional analysis
Journal of Clinical Oncology (2004)
Multicenter French analysis establishing prognostic factors and survival outcomes for CRS + HIPEC, forming the basis for national French peritoneal oncology guidelines.
Effect of Oxaliplatin With or Without Cetuximab on Disease-Free Survival Among Patients With Resected Stage III Colon Cancer
JAMA Surgery (PRODIGE 7) (2021)
Phase III RCT showing CRS alone non-inferior to CRS + oxaliplatin HIPEC in colorectal peritoneal metastases, reshaping HIPEC practice guidelines globally.
Cytoreductive surgery plus HIPEC for malignant peritoneal mesothelioma: a systematic review and meta-analysis
European Journal of Surgical Oncology (2019)
Comprehensive meta-analysis demonstrating survival benefit of CRS + HIPEC for peritoneal mesothelioma and identifying complete cytoreduction as the dominant prognostic factor.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 奥利维耶·格雷安 的研究动态
Follow Olivier Glehen's research updates
留下邮箱，当我们发布与 Olivier Glehen（Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment